Summary
Veradermics: VDPHL01 Looks Promising Enough On Paper
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.
Veradermics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 3,368 | $402,038.16 | $385,332.88 | -$16,705.28 | -4.16% |
| MM Mike Masters Masters Capital Management LLC | 100,000 | $6.32M | $11.27M | $4.96M | 78.48% |
| NM Nir Messafi Deep Track Capita LLP | 2M | $210.63M | $195.51M | -$15.12M | -7.18% |
 Joseph Castro Nuveen LLC | 47,894 | $5.89M | $4.68M | -$1.21M | -20.49% |
| MPM Mark P. Mennitt CenterBook Partners LP | 42,357 | $5.06M | $4.14M | -$915,546.56 | -18.11% |
Veradermics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mayank Mamtani B. Riley Securities | 473.28 | $48,440.52 | $46,111.97 | -$2,328.55 | -4.81% |
Veradermics Inc. (MANE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Veradermics Inc. ever had a stock split?
Veradermics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Reid Waldman CEO | NYSE Exchange | 922967104 CUSIP |
| US Country | 37 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Veradermics, Incorporated is a biopharmaceutical company dedicated to the development of innovative therapeutics targeting dermatologic and aesthetic conditions. Established in 2019 and headquartered in New Haven, Connecticut, the company is particularly focused on addressing Pattern Hair Loss (PHL) in both adults and children. Its mission encompasses the creation of advanced treatments that offer effective solutions for various skin-related ailments and enhance aesthetic outcomes. Through its pioneering research and development efforts, Veradermics aims to provide valuable contributions to the healthcare community involved in dermatology, catering to healthcare providers and clinicians who treat a diverse range of dermatologic conditions.
Products and Services
- VDPHL01:
This is an oral, non-hormonal treatment designed specifically for men and women experiencing chronic hair loss due to Pattern Hair Loss (PHL). Its development is aimed at providing an effective alternative to hormonal therapies, making it suitable for a wider demographic including both genders.
- VDMN:
This innovative product features a dissolvable microarray patch technology aimed at delivering immunotherapy for common warts. The unique delivery system enhances patient compliance and efficacy in treatment by allowing for localized and controlled administration.
- VDAA:
VDAA is being developed for the treatment of alopecia areata, an autoimmune condition that causes hair loss. This product aims to address the needs of patients suffering from this challenging condition, offering a potential therapeutic option that targets the underlying causes of hair loss.
- VDMC:
VDMC is focused on the treatment of molluscum contagiosum, a common viral skin infection. By developing effective treatment options, the company seeks to improve the patient experience and provide viable solutions for managing this condition.
- Atopic Dermatitis Treatments:
In addition to its other offerings, Veradermics is involved in research aimed at developing therapies for atopic dermatitis, a chronic inflammatory skin condition. The goal is to create effective and safe treatments to alleviate symptoms experienced by affected individuals.
